TY  - JOUR
AU  - Suarez-Carmona, Meggy
AU  - Halama, Niels
TI  - Neoadjuvant combination immunotherapy in MSI/dMMR colorectal cancer.
JO  - Trends in cancer
VL  - 10
IS  - 12
SN  - 2405-8033
CY  - Amsterdam
PB  - Elsevier
M1  - DKFZ-2024-02163
SP  - 1093-1094
PY  - 2024
N1  - #EA:D196#LA:D196# / 2024 Dec;10(12):1093-1094 / HI-TRON / SPOTLIGHT
AB  - Neoadjuvant immune checkpoint inhibition (ICI) is a new approach to treat patients with colorectal cancer (CRC). The effects of combined neoadjuvant ICI in locally advanced, DNA mismatch repair (dMMR)-deficient/microsatellite instable (MSI) CRC were recently reported by de Gooyer et al. from the NICHE-3 trial. Further studies will determine whether these impressive pathological responses lead to long-term clinical benefit.
KW  - MSI (Other)
KW  - colorectal cancer (Other)
KW  - dMMR (Other)
KW  - immune checkpoint inhibition (Other)
KW  - neoadjuvant therapy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:39448335
DO  - DOI:10.1016/j.trecan.2024.10.006
UR  - https://inrepo02.dkfz.de/record/294330
ER  -